|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cloning and sequencing of the monocarboxylate transporter from mouse Ehrlich Lettré tumour cell confirms its identity as MCT1 and demonstrates that glycosylation is not required for MCT1 function.
|
8603082 |
1996 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoma samples displaying reduced levels of MCT1 were found to express the high affinity glucose transporter, GLUT1, suggesting that there is a switch from butyrate to glucose as an energy source in colonic epithelia during transition to malignancy.
|
11953883 |
2002 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoma samples displaying reduced levels of MCT1 were found to express the high affinity glucose transporter, GLUT1, suggesting that there is a switch from butyrate to glucose as an energy source in colonic epithelia during transition to malignancy.
|
11953883 |
2002 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Analysis of healthy colonic tissues and carcinomas using immunohistochemistry and Western blotting revealed a significant decline in the expression of MCT1 protein during transition from normality to malignancy.
|
11953883 |
2002 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined a diverse panel of lymphoid malignancies for the expression of MCT-1.
|
12637315 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that high levels of MCT-1 protein may be associated with a high-risk subset of lymphoid neoplasms and may further support the potential role of MCT-1 in promoting human lymphoid tumor development.
|
12637315 |
2003 |
|
Diffuse Large B-Cell Lymphoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identified a subset of primary diffuse large B-cell lymphomas that exhibited elevated levels of MCT-1 protein.
|
12637315 |
2003 |
|
T-Cell Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our laboratory has recently discovered a novel candidate oncogene, MCT-1, amplified in human T-cell lymphoma and mapped to chromosome Xq22-24.
|
12637315 |
2003 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
There was no detectable MCT-1 protein in leukemic cells from patients with chronic lymphocytic leukemia or in any healthy lymphoid tissue examined.
|
12637315 |
2003 |
|
Lymphoma, Follicular
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, all transformed follicular lymphomas in our study demonstrated elevated protein levels of MCT-1.
|
12637315 |
2003 |
|
Malignant neoplasm of breast
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Reduced expression of GNA11 and silencing of MCT1 in human breast cancers.
|
12759536 |
2003 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Cellular invasion assays correlate with gene expression and zymography experiments identifying both Ox and MCT-1 as able to inhibit invasion of metastatic cancer cell lines through matrigel at nanomolar concentrations, with MCT-1 more effective than Ox in 2 of the 3 cancer cell lines assessed.
|
15122596 |
2004 |
|
Glioblastoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT 1 and 2 were the primary isoforms expressed in human glioblastoma multiforme and glioma-derived cell lines.
|
15574223 |
2004 |
|
Glioblastoma Multiforme
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT 1 and 2 were the primary isoforms expressed in human glioblastoma multiforme and glioma-derived cell lines.
|
15574223 |
2004 |
|
T-Cell Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Multiple copies in T-cell maligancy (MCT-1) is a putative oncogene initially identified in a human T-cell lymphoma.
|
15897892 |
2005 |
|
Malignant transformation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data shed light on the role of MCT-1 in the cellular response to DNA damage and its involvement in malignant transformation.
|
15897892 |
2005 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that MCT-1 may contribute to the pathogenesis and progression of human breast cancer via at least two routes: promotion of angiogenesis through the decline of TSP1 and inhibition of apoptosis.
|
16322206 |
2005 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of a novel oncogene MCT-1 (multiple copies in a T cell malignancy) causes malignant transformation of murine fibroblasts.
|
16322206 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a tumor xenograft model, MCT-1-overexpressing cells showed higher take rates and formed significantly larger tumors than MCF7-EV controls.
|
16322206 |
2005 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that MCT-1 may contribute to the pathogenesis and progression of human breast cancer via at least two routes: promotion of angiogenesis through the decline of TSP1 and inhibition of apoptosis.
|
16322206 |
2005 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of a novel oncogene MCT-1 (multiple copies in a T cell malignancy) causes malignant transformation of murine fibroblasts.
|
16322206 |
2005 |
|
Malignant transformation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of a novel oncogene MCT-1 (multiple copies in a T cell malignancy) causes malignant transformation of murine fibroblasts.
|
16322206 |
2005 |
|
Immunosuppression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monocarboxylate transporter MCT1 is a target for immunosuppression.
|
16370372 |
2005 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of MCT-1 and PsiMCT-1 might provide clues to cancer genes and their evolution across species.
|
16815567 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of MCT-1 and PsiMCT-1 might provide clues to cancer genes and their evolution across species.
|
16815567 |
2006 |